An author in JAMA points out some caveats to a ground-breaking trial.
How aggressive should doctors be in treating hypertension? The “consensus” seems ever in flux, as new studies emerge. Aram V. Chobanian, MD, of Boston University Medical Center, offered a viewpoint in the current issue of JAMA that takes another look at this question in light of results from SPRINT, the Systolic Blood Pressure Intervention Trial, which upended years of thinking about the benefits of treating older patients with some health risks. Some called SPRINT the most important cardiovascular trial in 40 years.
SPRINT examined the benefit of getting these patients to a goal of having their systolic blood pressure (BP) to 120 mm Hg, and found that in general, it took 1 additional drug to get patients to this goal. The benefits that emerged were so apparent that the National Institutes of Health stopped the trial early. The group being treated aggressively had 25% fewer deaths and 30% fewer cardiovascular events.
Chobianian noted that the exclusion criteria of SPRINT were such that primary care physicians—who provide the vast majority of care to this population—should take this knowledge into account. And, because of the early end to the trial for ethical reasons, “the full effect of the benefits and adverse events of long-term therapy is unknown.” Of note, he wrote, BP measurements in SPRINT were made after a short period of rest, which is not typical in clinical practice settings.
So, what to do with treatment guidelines? Chobanian offers a recommendation to treat those without high health risk to <120/80 mm Hg up to age 50, and then to treat those between age 50 and 74 to a systolic BP of <130 mm Hg. After age 75, the systolic BP should be <140 mm Hg If the patient has type 2 diabetes, the systolic BP goal should be <140 mm Hg.
“Treatment decisions should continue to be guided by the actual BP values, although other factors need to be considered,” Chobanian wrote. Patients will keep arriving, and as doctors know, “treatment decisions and recommendations may be required even when the evidence base is not conclusive.”
What’s more important, he said, is for doctors to emphasize the need for healthy lifestyles for those in the 130-139/80-85 mm Hg range.
Reference
Chobanian AV. Hypertension in 2017—what is the right range? JAMA. 2017; 317(6):579-580. doi:10.1001/jama.2017.0105.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More